COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?

Slides:



Advertisements
Similar presentations
Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.
Advertisements

Lifestyle Modifications
What's New in Basal Insulin for Diabetes
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Insulin and Incretins: the perfect Partnership?
Short-, Intermediate-, Long-Acting Insulins
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL
Special Consideration in Insulin Therapy
Faster-Acting Insulins
Case 53-year-old Black Man
New Patient-Friendly Options for Managing Insulin Dosing
Glaucoma Progression.
The Next Generation of Basal Insulins
Global Projections for Diabetes:
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Insulin Innovation.
Insulin/GLP-1 Agonist Combinations
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.
How Early Should Basal Insulin Be Used in T2D Management?
Updates Abound.
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Emerging Basal Insulins for Diabetes
GLP-1 Receptor Agonists: How Early Is Appropriate?
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Insulin/GLP-1 Agonist Combinations
Insulin Use in Primary Care: Practice Challenges
Insulin Innovation.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?
Novel Approaches to T1D Management
T2DM Management.
Better Diabetes Control With Novel Basal Insulins
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Insulin Innovation.
Insulin in Diabetes Management: Effective Patient Selection Is Key
Add-On Therapy to Insulin in T1DM Management
Improving Effective Basal Insulin Use in Clinical Practice
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Getting PPG Under Control
Emerging Combination Injectable Therapy A New Era in Diabetes Care
ADA/EASD general recommendations for type 2 diabetes management (1).
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future
Fixed-Ratio Combination Therapy in T2DM
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Emerging Basal Insulins for Diabetes
The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?
Fresh perspectives ON BASAL Insulins in diabetes care
In the Know.
The Challenge of Insulin Titration
Presentation transcript:

COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?

Insulin Therapy in T2DM

Agenda

ADA/EASD Recommendations for T2DM Management: The Role of Injectables

Intensification Options for Insulin Therapy

Complementary Effects of Basal Insulin and GLP-1 RA Therapy

Complementary Actions of GLP-1 RA and Insulin

Fixed-Ratio Combinations of Basal Insulin and GLP-1 RAs

IGlarLixi Proof-of-Concept Study

IDegLira Fixed-Ratio Combination Dosing Regimen

IDegLira in Insulin-Naive T2DM Patients Study Design: DUAL I

IDegLira in Insulin-Naive T2DM Patients: Glycemic Control

IDegLira in Insulin-Naive T2DM Patients: Glycemic Control (cont)

IDegLira in Insulin-Naive T2DM Patients: Weight

IDegLira in Insulin-Naive T2DM Patients: Hypoglycemia

IDegLira in Insulin-Naive T2DM Patients: Nausea

Practical Aspects of Using Fixed-Ratio Basal Insulin/GLP-1 RA Combinations

Conclusions

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.